255 related articles for article (PubMed ID: 4598802)
41. [Suspected multiple sclerosis].
Pellkofer H; Hohlfeld R
MMW Fortschr Med; 2006 Mar; 148(13):63-4. PubMed ID: 16642711
[No Abstract] [Full Text] [Related]
42. [Current methods of the multiple sclerosis treatment].
Kovalenko PA; Shamanskiĭ SV; Baziĭ NI
Voen Med Zh; 2001 Oct; 322(10):45-52. PubMed ID: 11764483
[No Abstract] [Full Text] [Related]
43. [Multiple sclerosis--immunopathogenesis, traditional therapeutic strategy and suggested combined immunotherapy].
Skotnicki AB; Aleksandrowicz J; Retinger-Grzesiuła M; Zduńczyk A; Grochmal S; Huczyński J
Postepy Hig Med Dosw; 1983; 37(1):1-32. PubMed ID: 6356094
[No Abstract] [Full Text] [Related]
44. Plasmapheresis, lymphocytapheresis, and immunosuppressive drug therapy in multiple sclerosis.
Hauser SL; Fosburg M; Kevy S; Weiner HL
Prog Clin Biol Res; 1982; 106():239-54. PubMed ID: 6184727
[TBL] [Abstract][Full Text] [Related]
45. [Mitoxantrone, a new reality].
Ruiz-Peña JL; Izquierdo G
Rev Neurol; 2003 Apr 1-15; 36(7):698-9. PubMed ID: 12666055
[No Abstract] [Full Text] [Related]
46. Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.
Lance EM; Kremer M; Abbosh J; Jones VE; Knight S; Medawar PB
Clin Exp Immunol; 1975 Jul; 21(1):1-12. PubMed ID: 1237376
[TBL] [Abstract][Full Text] [Related]
47. [New therapeutic possibilities for disseminated sclerosis?].
Wanscher B; Sørensen PS
Ugeskr Laeger; 1994 Oct; 156(43):6353-8. PubMed ID: 7810008
[TBL] [Abstract][Full Text] [Related]
48. [Immunosuppressive medication in multiple sclerosis].
García Merino JA
Rev Neurol; 2002 Dec 16-31; 35(12):1154-8. PubMed ID: 12497298
[TBL] [Abstract][Full Text] [Related]
49. Multiple sclerosis.
Poser CM
Med Clin North Am; 1979 Jul; 63(4):729-43. PubMed ID: 381806
[No Abstract] [Full Text] [Related]
50. Etiologic correlations between idiopathic polyneuritis and multiple sclerosis: therapeutic implications.
Arnason BG; Mantos JJ
Mod Treat; 1970 Sep; 7(5):903-17. PubMed ID: 4326376
[No Abstract] [Full Text] [Related]
51. Immunology of multiple sclerosis.
Kibler RF; Paty DW; Sherr V
Res Publ Assoc Res Nerv Ment Dis; 1971; 49():95-111. PubMed ID: 5133707
[No Abstract] [Full Text] [Related]
52. [Guidelines for drug treatment of multiple sclerosis].
Kollegger H; Vass K; Marschall I; Koch G; Deecke L
Wien Klin Wochenschr; 1993; 105(16):443-52. PubMed ID: 7692677
[TBL] [Abstract][Full Text] [Related]
53. Antibodies to oligodendroglia in multiple sclerosis.
Abramsky O; Lisak RP; Silberberg DH; Pleasure D
Trans Am Neurol Assoc; 1977; 102():15-8. PubMed ID: 616097
[No Abstract] [Full Text] [Related]
54. Relapse in multiple sclerosis.
Galea I; Ward-Abel N; Heesen C
BMJ; 2015 Apr; 350():h1765. PubMed ID: 25872511
[No Abstract] [Full Text] [Related]
55. Clinical spectrum of multiple sclerosis.
Reder AT; Antel JP
Neurol Clin; 1983 Aug; 1(3):573-99. PubMed ID: 6095009
[TBL] [Abstract][Full Text] [Related]
56. New treatments for multiple sclerosis.
Hallpike JF
Br J Hosp Med; 1980 Jan; 23(1):63-4, 66, 68. PubMed ID: 6153540
[No Abstract] [Full Text] [Related]
57. [Treatment of autoimmune dermatoses].
Braun-Falco O; Marghescu S
Arch Belg Dermatol Syphiligr; 1969; 25(2):269-81. PubMed ID: 5401546
[No Abstract] [Full Text] [Related]
58. Anti-neuroglial and anti-neuronal cell factors in experimental allergic encephalomyelitis and multiple sclerosis.
Bornstein MB
Int Arch Allergy Appl Immunol; 1969; 36():Suppl:574-607. PubMed ID: 4906733
[No Abstract] [Full Text] [Related]
59. Viruses isolated from patients with encephalomyelitis and multiple sclerosis. I. Pathogenic and antigenic properties.
Bychkova EN
Fed Proc Transl Suppl; 1965; 24(4):742-4. PubMed ID: 4953628
[No Abstract] [Full Text] [Related]
60. From etiology and pathogenesis to therapy of multiple sclerosis.
Cazzullo CL
Boll Ist Sieroter Milan; 1978 Jan; 56(6):622-33. PubMed ID: 580220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
